InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

PharmaCyte Biotech, Inc.

PMCB Clue Score43
United States Fiscal year ends April CIK 0001157075
$0.40 +1.76% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $0.40 −86.70% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 12 Oct 2016. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2017Revenue0.0Operating income−4.4Net income−4.4Fiscal year 2018Revenue0.0Operating income−7.0Net income−6.8Fiscal year 2019Revenue0.0Operating income−4.1Net income−4.1Fiscal year 2020Revenue0.0Operating income−3.8Net income−3.8Fiscal year 2021Revenue0.0Operating income−3.6Net income−3.6EPS, diluted−2.45Fiscal year 2022Revenue0.0Operating income−4.4Net income−4.2EPS, diluted−0.27Fiscal year 2023Revenue0.0Operating income−6.5Net income−4.3EPS, diluted−0.22Fiscal year 2024Revenue0.0Operating income−8.5Net income0.3EPS, diluted−1.80Fiscal year 2025Revenue0.0Operating income−4.4Net income30.7 +9,085.0%EPS, diluted3.19Fiscal year 2026Revenue0.0Operating income−6.9Net income−19.4 −163.4%EPS, diluted−2.77
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Revenue 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Growth
Operating income −4.4 −7.0 −4.1 −3.8 −3.6 −4.4 −6.5 −8.5 −4.4 −6.9
Net income −4.4 −6.8 −4.1 −3.8 −3.6 −4.2 −4.3 0.3 30.7 −19.4
Growth +9,085.0% −163.4%
EPS, diluted n/a n/a n/a n/a −2.45 −0.27 −0.22 −1.80 3.19 −2.77

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flow
Fiscal year 2017Operating cash flow−3.3Fiscal year 2018Operating cash flow−5.1Fiscal year 2019Operating cash flow−2.9Fiscal year 2020Operating cash flow−2.3Fiscal year 2021Operating cash flow−3.3Fiscal year 2022Operating cash flow−4.1Buybacks0.0Fiscal year 2023Operating cash flow−3.8Buybacks−13.6Fiscal year 2024Operating cash flow−2.2Buybacks−28.2Fiscal year 2025Operating cash flow−3.0Buybacks−2.5Fiscal year 2026Operating cash flow−5.2Buybacks−0.4
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Operating cash flow −3.3 −5.1 −2.9 −2.3 −3.3 −4.1 −3.8 −2.2 −3.0 −5.2
Buybacks n/a n/a n/a n/a n/a 0.0 −13.6 −28.2 −2.5 −0.4

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2017Shareholders’ equity8.1Fiscal year 2018Shareholders’ equity5.8Fiscal year 2019Shareholders’ equity5.0Fiscal year 2020Cash0.9Shareholders’ equity5.1Fiscal year 2021Cash2.2Shareholders’ equity6.7Fiscal year 2022Cash85.4Shareholders’ equity89.9Fiscal year 2023Cash68.0Shareholders’ equity72.7Fiscal year 2024Cash50.2Shareholders’ equity27.6Fiscal year 2025Cash15.2Shareholders’ equity51.9Fiscal year 2026Cash18.6Shareholders’ equity33.3
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Cash n/a n/a n/a 0.9 2.2 85.4 68.0 50.2 15.2 18.6
Shareholders’ equity 8.1 5.8 5.0 5.1 6.7 89.9 72.7 27.6 51.9 33.3

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2026 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending April, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2017 30 Apr 2017 FY2018 30 Apr 2018 FY2019 30 Apr 2019 FY2020† 30 Apr 2020 FY2021† 30 Apr 2021 FY2022† 30 Apr 2022 FY2023 30 Apr 2023 FY2024† 30 Apr 2024 FY2025 30 Apr 2025 FY2026 30 Apr 2026
Revenue and profit
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Growth
1.2 2.0 0.5 0.3 0.9 0.7 0.5 0.4 0.4 0.4
0.7 1.8 1.4 1.2 0.4 1.1 1.1 6.1 3.9 4.9
−4.4 −7.0 −4.1 −3.8 −3.6 −4.4 −6.5 −8.5 −4.4 −6.9
Growth
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
−4.4 −6.8 −4.1 −3.8 −3.6 −4.2 −4.3 0.3 30.7 −19.4
Growth +9,085.0% −163.4%
Per share
n/a n/a n/a n/a −2.45 −0.27 −0.22 −1.80 3.19 −2.77
n/a n/a n/a n/a −2.45 −0.27 −0.22 −1.80 3.19 −2.77
Growth −186.8%
845.3 968.6 1,100 0.9 1.4 15.5 19.5 9.6 7.3 8.4
845.3 968.6 1,100 0.9 1.4 15.5 19.5 9.6 7.3 8.4
Growth +14.6% +13.6% −99.9% +60.2% +971.7% +25.6% −50.8% −23.5% +14.3%

† The diluted share count jumps at 2020 and 2021 and 2022 and 2024, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 8 of 10 years on file.